STRENGTHENED warnings about the risk of next-day drowsiness after taking Zolpidem are to be included in revised product information, following a safety review by the European Medicines Agency. The review of Zolpidem, used for the short-term treatment of insomnia, was launched in light of reports of impaired driving or road accidents involving people who had taken the drug the night before. The EMA's Pharmacovigilance Risk Assessment Committee has advised that the existing 10mg daily dose detailed in the current product information must not be exceeded. Patients should take the lowest possible dose just before going to bed and should not take additional doses on the same night, according to PRAC recommendations following the review.
展开▼
